Myriad Genetics' Test Added In Disease Activity Measure List
Zacks Investment Research | Nov 21, 2019 10:01PM ET
Myriad Genetics, Inc. (NASDAQ:MYGN) announced that its Vectra test was included by the American College of Rheumatology (“ACR”) in its list of recommended disease activity measures for patients with rheumatoid arthritis (RA). Per the recommendation, published in the Arthritis Care & Research journal, Vectra is among 11 disease activity measures, which meet a minimum standard, considering disease activity states and feasibility for regular clinical use.
With the recent recognition, which is a stepping stone to expand its offerings in RA, Myriad Genetics aims to strengthen foothold in the global autoimmune disease diagnostics market.
Few Words on Vectra
Vectra is a multi-biomarker molecular blood test, which provides an unbiased and tailored measure of inflammatory disease activity in patients with RA. Vectra helps to predict radiographic progression, enabling care providers to chalk out appropriate treatment plans for patients.
Vectra is one of the five commonly studied RA disease activity measures among the 46 assessed. Presently, there are more than 35 peer-reviewed Vectra journal publications.
Significance of the Inclusion
Management expects the inclusion of Vectra in the ACR’s recommendations for disease activity measures to provide an additional treatment option to medical practitioners. As the test accurately measures inflammation associated with RA, it will provide important information to physicians to make more informed treatment decisions to improve the outcome.
Myriad Genetics is optimistic about increased customer adoption of Vectra. The company is expecting the trend to continue as the ACR estimates that 1.5 million people are affected by RA in the United States.
Recent Developments
Myriad Genetics presented favorable data related to the Vectra test at the 2019 ACR/ARP Annual Meeting in Atlanta, GA, in November. The key focus of the studies on the test was to predict the risk of a cardiovascular (CV) event in people with RA with the Vectra score in combination with other clinical measures and the risk of radiographic progression (RP) within a year.
Industry Prospects
Per a report by Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.